Ken Griffin Crispr Therapeutics Ag Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $6.36 Million - $8.47 Million	-124,300 Reduced 14.88%	710,800 $38.4 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $19.1 Million - $28.1 Million	-315,400 Reduced 27.41%	835,100 $56.9 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $29.3 Million - $54.8 Million	759,400 Added 194.17%	1,150,500 $72 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $753,474 - $979,400	-16,600 Reduced 4.07%	391,100 $17.8 Million
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $9.65 Million - $15 Million	221,900 Added 119.43%	407,700 $22.9 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $11.5 Million - $15.8 Million	-281,100 Reduced 60.21%	185,800 $8.4 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $9.37 Million - $15.7 Million	239,100 Added 104.96%	466,900 $19 Million
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $17.6 Million - $24.1 Million	-288,100 Reduced 55.84%	227,800 $14.9 Million

503

57M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.28B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.